A single-institution study of stereotactic body radiotherapy for patients with unresectable visceral pulmonary or hepatic oligometastases

Radiation Oncology

Eric Lartigau³  Hajer Jerraya¹  Thomas Lacornerie³  Bernard Prevost³  Xavier Mirabel³  Andrew Kramar²  Sylvain Dewas³  Jean-Emmanuel Bibault³  Ingrid Fumagalli³ 

[1] Medical Imaging Department, Oscar Lambret Comprehensive Cancer Center, Lille, France;Biostatistics Department, Oscar Lambret Comprehensive Cancer Center, Lille, France;Radiation Therapy Department, Oscar Lambret Comprehensive Center Lille, 3 rue Combemale, Lille cedex, 59020, France

关键词: CyberKnife;    Oligometastases;    Lung metastasis;    Liver metastasis;    SBRT;   

Others  :  1155255
DOI  :  10.1186/1748-717X-7-164

 received in 2012-06-12, accepted in 2012-09-22,  发布年份 2012

【 摘 要 】

Purpose

The purpose of this study is to evaluate the feasibility, efficacy and toxicity of SBRT for treatment of unresectable hepatic or lung metastases regardless of their primary tumor site for patients who received prior systemic chemotherapy.

Methods and materials

Between July 2007 and June 2010, 90 patients were treated with the CyberKnife® SBRT system for hepatic or pulmonary metastatic lesions. Medical records were retrospectively reviewed. The endpoints of this study were local control, overall survival (OS), disease-free survival (DFS), local relapse free-survival (LRFS), and treatment toxicity.

Results

A total of 113 liver and 26 lung metastatic lesions in 52 men (58%) and 38 women (42%) were treated. Median follow-up was 17 months. Median age at treatment was 65 years (range, 23–84 years). Primary cancers were 63 GI, three lung, eight breast, four melanoma, three neuro-endocrine tumors, and three sarcomas. Median diameter of the lesions was 28 mm (range, 7–110 mm) for liver and 12.5 mm (range, 5–63.5 mm) for lung. Local control rates at 1 and 2 years were 84.5% and 66.1%, respectively. Two-year overall survival rate was 70% (95% CI: 55–81%). The 1 and 2-year disease-free survival rates were 27% (95% CI: 18–37%) and 10% (95% CI: 4–20%), respectively. Median duration of disease-free survival was 6.7 months (95% CI: 5.1–9.5 months). Observed toxicities included grade 1–3 acute toxicities. One grade 3 and no grade 4 toxicity were reported.

Conclusion

High-dose SBRT for metastatic lesions is both feasible and effective with high local control rates. Overall survival is comparable with other available techniques. Treatment is well tolerated with low toxicity rates. It could represent an interesting treatment option for oligometastatic patients not amenable to surgery, even when patients had been pre-treated with chemotherapy.

Summary

Stereotactic body radiotherapy (SBRT) has previously been successfully used in the treatment of metastatic lesions. It could be considered as a curative option for oligometastatic patients. This retrospective study involved 90 patients, designed to test potential effectiveness of SBRT in the treatment of oligometastases irrespective of primary. Results suggest SBRT could be an effective treatment extending patients’ life span. This treatment appears to be more effective when used prior to multiple systemic treatment regimens.

【 授权许可】

   
2012 Fumagalli et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Herfarth KK, Debus J, Lohr F, Bahner ML, Rhein B, Fritz P, et al.: Stereotactic single-dose radiation therapy of liver tumors: results of a phase I/II trial. J Clin Oncol 2001, 19(1):164.
• [2]Schefter TE, Kavanagh BD, Timmerman RD, Cardenes HR, Baron A, Gaspar LE: A phase I trial of stereotactic body radiation therapy (SBRT) for liver metastases. Int J RadiationOncology* Biology* Physics 2005, 62(5):1371-1378.
• [3]Timmerman R, Papiez L, McGarry R, Likes L, DesRosiers C, Frost S, et al.: Extracranial stereotactic radioablation: results of a phase I study in medically inoperable stage I non-small cell lung cancer. Chest 2003, 124(5):1946-1955.
• [4]Schefter TE, Kavanagh BD, Raben D, Kane M, Chen C, Stuhr K, et al.: A phase I/II trial of stereotactic body radiation therapy (SBRT) for lung metastases: Initial report of dose escalation and early toxicity. Int J Radiat Oncol Biol Phys 2006, 66(4):S120-S127.
• [5]Hellman S, Weichselbaum RR: Oligometastases. J Clin Oncol 1995, 13(1):8-10.
• [6]Milano MT, Katz AW, Zhang H, Okunieff P: Oligometastases Treated With Stereotactic Body Radiotherapy: Long-Term Follow-Up of Prospective Study. Int J RadiationOncology, Biology, Physics 2012, 83(3):878-886.
• [7]Macdermed DM, Weichselbaum RR, Salama JK: A rationale for the targeted treatment ofoligometastases with radiotherapy. J Surg Oncol 2008, 98(3):202-206.
• [8]Okunieff P, Petersen AL, Philip A, Milano MT, Katz AW, Boros L, et al.: Stereotactic body radiation therapy (SBRT) for lung metastases. Acta Oncol 2006, 45(7):808-817.
• [9]Kavanagh BD, McGarry RC, Timmerman RD: Extracranial Radiosurgery (Stereotactic Body RadiationTherapy) for Oligometastases. Semin Radiat Oncol 2006, 16(2):77-84. avr
• [10]Katz AW, Carey-Sampson M, Muhs AG, Milano MT, Schell MC, Okunieff P: Hypofractionated stereotactic body radiation therapy (SBRT) for limited hepatic metastases. International Journal ofRadiation Oncology* Biology* Physics 2007, 67(3):793-798.
• [11]Rusthoven KE, Kavanagh BD, Burri SH, Chen C, Cardenes H, Chidel MA, et al.: Multi-institutional phase I/II trial of stereotactic body radiation therapy for lung metastases. J Clin Oncol 2009, 27(10):1579.
• [12]McCammon R, Schefter TE, Gaspar LE, Zaemisch R, Gravdahl D, Kavanagh B: Observation of a dose-control relationship for lung and liver tumors after stereotactic body radiation therapy. Int J Radiation Oncology* Biology* Physics 2009, 73(1):112-118.
• [13]Salama JK, Hasselle MD, Chmura SJ, Malik R, Mehta N, Yenice KM, et al.: Stereotactic bodyradiotherapy for multisite extracranial oligometastases: Final report of a dose escalation trial in patients with 1 to 5 sites of metastatic disease. Cancer 2012, 118(11):2962-2970.
• [14]Wulf J, Haedinger U, Oppitz U, Thiele W, Mueller G, Flentje M: Stereotactic radiotherapy for primary lung cancer and pulmonary metastases: a noninvasive treatment approach in medically inoperable patients. Int J Radiat Oncol Biol Phys 2004, 60(1):186-196.
• [15]Siva S, MacManus M, Ball D: Stereotactic radiotherapy for pulmonary oligometastases: a systematic review. J Thorac Oncol 2010, 5(7):1091.
• [16]Ricardi U, Filippi AR, Guarneri A, Ragona R, Mantovani C, Giglioli F, et al.: Stereotactic body radiation therapy for lung metastases. Lung Cancer 2012, 75(1):77-81.
• [17]Rusthoven KE, Kavanagh BD, Cardenes H, Stieber VW, Burri SH, Feigenberg SJ, et al.: Multi-Institutional Phase I/II Trial of Stereotactic Body Radiation Therapy for Liver Metastases. Journal ofClinical Oncology 2009, 27(10):1572-1578. avr 1
• [18]Lee MT, Kim JJ, Dinniwell R, Brierley J, Lockwood G, Wong R, et al.: Phase I study of individualized stereotactic body radiotherapy of liver metastases. J Clin Oncol 2009, 27(10):1585.